The Michael J. Fox Foundation (MJFF), the National Institutes of Health (NIH) and five life sciences companies announced a public-private partnership to advance understanding, measurement and treatment of Parkinson’s disease. The latest focus of the NIH Accelerating Medicines Partnership (AMP) model, this new AMP PD project will apply cutting-edge technologies to tease apart microscopic differences in the cells of people with Parkinson’s disease (PD).
To know more:
Apomorphine (MOVAPO) has received a positive recommendation by CADTH, the Canadian Agency for Drugs and Technologies in Health.
A positive recommendation means CADTH is recommending that the provinces offer public coverage for the cost of the drug for patients (with conditions):
Here’s the full recommendation report from CADTH: https://cadth.ca/sites/default/files/cdr/complete/SR0527_Movapo_complete-Jan-25-18.pdf